Call2Halt19

mRNA Vaccines and Cancer. ianbrighthope.substack.com/p… The authors’ final position is that the platform’s long-term risks remain unresolved. Under the principle of primum non nocere—first, do no harm—these risks should be independently and transparently investigated before the technology is used more widely in the general population or in patients with residual cancer. My Opinion As a physician who has spent more than four decades concerned with prevention, immune resilience and the ethical practice of medicine, I regard this paper as a grave warning that cannot responsibly be dismissed. The study does not provide final proof that mRNA vaccines cause every cancer reported after vaccination, nor do the authors claim that every recipient is destined to develop cancer. What it does provide is something that should deeply concern every doctor, scientist and regulator: a coherent description of 35 possible cancer-promoting mechanisms, supported to varying degrees by laboratory research, clinical observations and population data. The significance lies not in any single mechanism considered in isolation. It lies in their convergence. The paper describes the simultaneous activation of cancer-promoting pathways, interference with p53 and DNA repair, inflammatory effects of lipid nanoparticles, residual plasmid DNA, abnormal protein production through frameshifting, impaired immune surveillance, cytotoxic T-cell exhaustion and the possible awakening of dormant malignant cells. These are not trivial theoretical matters. They involve some of the most fundamental biological systems protecting us from cancer. I am particularly concerned that the greatest danger may not be the creation of a completely new cancer in an otherwise healthy person. It may be the acceleration of a cancer that is already present but microscopic, dormant or controlled by the immune system. Many people unknowingly carry abnormal cells, dormant micrometastases or early malignant clones. Under normal circumstances, these may remain controlled for years. If several cancer-promoting pressures are applied at the same time, that period of control could conceivably be compressed from years into months, weeks or even days. That is the central meaning of what has become known as “turbo cancer”: unusually rapid progression, recurrence, reactivation or metastatic spread. The expression is not yet a formally accepted medical diagnosis, but the clinical pattern it describes deserves investigation rather than ridicule or censorship. The population findings are not conclusive, but they are troubling. The Italian and South Korean studies report associations between vaccination and several cancers. American cancer registries show increasing early-onset disease, while analyses of US mortality records identify a significant departure from previous cancer-death trends. These studies have limitations and cannot, by themselves, establish causation. Nevertheless, uncertainty must not be confused with reassurance. When biological mechanisms, clinical reports and population signals point in a similar direction, the proper scientific response is urgent investigation - not denial. The estimate of between approximately 119,000 and 197,000 excess American cancer deaths is especially serious. It must be independently audited using transparent methods and complete access to the underlying data. It should not be declared proven, but neither should it be ignored merely because it challenges the official narrative. If the estimate is substantially correct, it represents a public-health catastrophe. If it is incorrect, an independent analysis should demonstrate precisely why. I am also deeply concerned about the movement of this technology into cancer treatment. Patients with residual disease, genomic instability, previous chemotherapy or dormant micrometastases may be among the people most vulnerable to the mechanisms described in this paper. It is extraordinary that the same incompletely characterised platform is now being offered as a treatment to those who may be most susceptible to its unresolved risks. The termination of the BNT122-01 trial demands complete transparency. The treatment failed to outperform watchful waiting, and a numerical imbalance in overall survival was identified. The direction, size and causes of that imbalance have not been fully disclosed. Patients, doctors and the scientific community are entitled to see the complete arm-by-arm survival results. Commercial confidentiality cannot be allowed to conceal information concerning human life and death. The fundamental failure began when this technology was deployed on a global scale without adequate investigation of carcinogenicity, genotoxicity, systemic biodistribution, residual DNA, repeated dosing, abnormal protein production or long-term persistence. Short-term antibody measurements were treated as though they answered long-term safety questions. They did not. Passive surveillance was never capable of reliably identifying delayed, complex and multifactorial outcomes such as cancer acceleration. Informed consent was therefore seriously compromised. People cannot give genuine informed consent when important risks have not been investigated, when uncertainties are concealed or minimised, and when refusal is punished through mandates, employment restrictions, travel controls or social exclusion. Consent obtained under pressure is not freely given consent. I believe that the precautionary principle must now be applied. Broad preventive use of nucleoside-modified mRNA–LNP products should be suspended while these questions are independently investigated. Their expansion into patients with residual cancer should also be halted until convincing evidence demonstrates where the products travel, how long they persist, what proteins they produce and whether they influence recurrence, progression, metastasis or survival. Every cancer registry should record vaccination date, product, dose number and batch number. Researchers must be given access to the data needed to compare vaccinated and unvaccinated populations while properly accounting for infection, age, previous cancer, screening, smoking, environmental exposures and other confounding factors. Tumours developing after vaccination should be examined using genomic sequencing, circulating tumour DNA, proteomics, immune profiling, cancer stem-cell markers and testing for vaccine-derived material. These investigations must be conducted by genuinely independent scientists—not controlled by the manufacturers whose products are being examined or by institutions committed to defending earlier regulatory decisions. All protocols, data and results should be publicly available. I do not accept the proposition that we must wait for absolute proof while exposure continues and the technology is extended into new vaccines and cancer treatments. Medicine has never required certainty beyond all doubt before acting to prevent foreseeable harm. A credible safety signal requires investigation. Multiple converging signals require decisive precaution. The burden of proof now rests with those who manufacture, regulate and promote these products. They must demonstrate safety with transparent, independent and long-term evidence. The public should not be required to prove harm after being exposed. The first duty of medicine is not to defend a product, a corporation, a government or an institution. It is to protect the patient. Primum non nocere—first, do no harm—requires that these unresolved risks be investigated before further mass exposure occurs. Anything less would represent a profound abandonment of medical ethics, scientific responsibility and the public trust. Having stated the reasonable, I now wish to tell you the truth. These vaccines are truly carcinogenic. I cannot understand why I am the only person who has stated this fact in writing. Ian Brighthope

Pfizer-Type Lipid Nanoparticles Even Containing No mRNA Increase Metastatic Tumor Burden More Than 10-Fold in Mice With Cancer: Journal ‘Nano Today’ “We demonstrate that LNP administration promotes tumor metastasis by inducing a systemic inflammatory response,” study authors confirm. “LNPs exhibited a promotive effect on tumor metastasis.”

Did you know COVID-19 vaccines were approved under different legal rules than regular drugs? The Allison Inquiry has begun admitting evidence into the official Inquiry Record under Inquiry Rule 25, which allows the Chairperson and Inquiry Counsel to jointly admit documentary evidence. One of the first documents includes the chart below, comparing the legal approval process for regular drugs with the process used for the first COVID-19 vaccine approvals. The purpose of this evidence is to help the Inquiry examine how these vaccines were approved under Canadian law and to create a public record based on the source documents themselves. This is just the beginning. More evidence will be added to the Inquiry Record in the lead-up to the inquiry and as the hearings progress. More information available here: covidtestimony.com/exhibits-…

How cell membranes keep you alive [🎞️ thebrainmaze]